Bioworld by clarivate explores the future of car t therapy in mainland china in special report

Three-part report investigates rapid pipeline growth, partnerships, clinical trials ,  and patient access challenges in cancer treatment london , april 30, 2024 /prnewswire/ -- bioworld™ published by  clarivate plc (nyse:clvt), a leading global provider of transformative intelligence, explores the growing investment in car t therapy development in mainland china in a new series titled " china's car t market comes of age." the report examines the dynamic realm of car t-cell therapies in china, including the rapid pipeline growth, deals, clinical trials and challenging issues surrounding patient access to very expensive and effective cancer therapeutics.
CLVT Ratings Summary
CLVT Quant Ranking